Patents Examined by Magrab
  • Patent number: 4894386
    Abstract: This invention provides a series of novel heterocyclic aliphatic carboxamides of formula I in which the group >Z--Y--X< is selected from >C.dbd.CH--N<, >N--CH.dbd.C<, >C.dbd.N--N< and >N--N.dbd.C< and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.
    Type: Grant
    Filed: October 11, 1988
    Date of Patent: January 16, 1990
    Assignee: ICI Americas Inc.
    Inventors: Frederick J. Brown, Victor G. Matassa
  • Patent number: 4883877
    Abstract: Compounds of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are, for example, H, alkyl, cycloalkyl, aryl or alkaryl are suitable as an ammonium salt-forming component for acid pharmaceutical active ingredients, and in particular for the preparation of azabicyclo[3.1.1.]heptane-substituted alkanediphosphonic acids for the treatment of diseases which can be attributed to disturbances in calcium metabolism.
    Type: Grant
    Filed: October 31, 1988
    Date of Patent: November 28, 1989
    Assignee: Ciba-Geigy Corporation
    Inventor: Alex Alder
  • Patent number: 4883807
    Abstract: Compounds of the formula (I): ##STR1## and stereoisomers and salts thereof, wherein R.sup.1 and R.sup.2, are optionally substituted alkyl; V is either oxygen or sulphur; Y is hydrogen, optionally substituted alkyl, cyano, nitro or halogen; X is ##STR2## Z is NOR.sup.5 or ##STR3## A is CO.sub.2 R.sup.6, COR.sup.7, cyano, nitro or acylamino; B is hydrogen, optionally substituted alkyl, optionally substituted aryl, CO.sub.2 R.sup.8, COR.sup.9, cyano, nitro or acylamino, or A and B together form a ring containing one or more heteroatoms; R.sup.4 is CO.sub.2 R.sup.3 or R.sup.17 ; R.sup.12 is OR.sup.13, SR.sup.14, NR.sup.15 R.sup.16 or R.sup.18 ; R.sup.3 is optionally substituted alkyl;and R.sup.5 to R.sup.11 and R.sup.13 to R.sub.
    Type: Grant
    Filed: December 1, 1987
    Date of Patent: November 28, 1989
    Assignee: Imperial Chemical Industries PLC
    Inventors: John M. Clough, Christopher R. A. Godfrey, Paul J. de Fraine, Brian K. Snell
  • Patent number: 4882340
    Abstract: A novel benzofuran derivative of the formula: ##STR1## wherein R.sup.1 is hydrogen atom, a lower alkoxy group or a halogen atom, one of R.sup.2 and R.sup.3 is a lower alkyl group and the other is a lower alkyl group or a phenyl-lower alkyl group, or R.sup.2 and R.sup.3 combine together with adjacent nitrogen atom to form a heteromonocyclic group, Ring A is a substituted or unsubstituted phenyl group, Y is oxygen atom or sulfur atom and n is an integer of 2 or 3, or a pharmaceutically acceptable salt thereof is disclosed.The compound (I) or a pharmaceutically acceptable salt thereof has a potent inhibitory activity against reflective contractions of urinary bladder.
    Type: Grant
    Filed: September 2, 1988
    Date of Patent: November 21, 1989
    Assignee: Tanabe Seiyaku Co., Ltd.
    Inventors: Ikuo Iijima, Masakatsu Ozeki, Yutaka Saiga, Tohru Ishizuka, Kunio Nosaka
  • Patent number: 4880941
    Abstract: 2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-6-benzo [b] thiophene carboxylic acid labelled with tritium, its preparation and its use as a radioactive marker in the determination of the affinity of, the presence of, or the amount of, retinoids having a carboxylic group and/or in the characterization of antibodies directed against this acid and/or in the quantification of the cRABP receptor of said retinoids.
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: November 14, 1989
    Assignee: Centre International de Recherches Dermatologique (CIRD)
    Inventors: Braham Shroot, Oliver Watts, Joseph Gazith, Marie-Therese Cavey
  • Patent number: 4880802
    Abstract: For treatment of disorders of the central nervous system, the cardiovascular system or the intestinal tract, the new substituted basic 2-aminotetralins of the formula ##STR1## in which R.sup.1 represents hydrogen or alkyl,R.sup.2 represents hydrogen, alkyl or acyl, andR.sup.3 represents quinuclidine or a group of the formula --(CH.sub.2).sub.a --R.sup.4, --CH.sub.2 --CH.dbd.CH--(CH.sub.2).sub.b --R.sup.4, --CH.sub.2 --C.tbd.(CH.sub.2).sub.b --R.sup.4, ##STR2## wherein a denotes a number from 1 to 10,b denotes a number 0, 1, 2, 3 or 4,d denotes a number 2 or 3, andX denotes oxygen, sulphur, or NR.sup.5,and their salts.
    Type: Grant
    Filed: December 8, 1987
    Date of Patent: November 14, 1989
    Assignee: Bayer Aktiengesellschaft
    Inventors: Rudolf Schohe, Thomas Glaser, Jorg Traber, George S. Allen
  • Patent number: 4876271
    Abstract: Novel substituted thieno[3,2-b]thiophene-2-sulfonamides are prepared by novel synthetic processes. These compounds are useful for the treatment of elevated intraocular pressure in compositions including ophthalmic drops and inserts.
    Type: Grant
    Filed: December 20, 1988
    Date of Patent: October 24, 1989
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, John D. Prugh
  • Patent number: 4876270
    Abstract: Novel substituted .alpha.,.alpha.-diphenylethylene derivatives of formula I ##STR1## in which R.sub.1 and R.sub.4 independently of one another each represents hydrogen, hydroxy, C.sub.1 -C.sub.5 -alkyl, C.sub.1 -C.sub.8 -alkoxy, C.sub.1 -C.sub.3 -alkoxy substituted by from 1 to 7 halogen atoms, alkoxyalkoxy having a total of from 2 to 6 carbon atoms, C.sub.3 -C.sub.5 -alkenyloxy or C.sub.3 -C.sub.5 -alkynyloxy;R.sub.2 and R.sub.3 independently of one another each represents hydrogen, halogen, C.sub.1 -C.sub.3 -alkyl, C.sub.1 -C.sub.5 -alkoxy or nitro; orR.sub.1 and R.sub.2 together represent a radical --O--CH.sub.2 --O-- or --O--CH.sub.2 --CH.sub.2 --O--;R.sub.5 and R.sub.6 independently of one another each represents hydrogen, halogen or methyl;R.sub.7 and R.sub.
    Type: Grant
    Filed: February 10, 1988
    Date of Patent: October 24, 1989
    Assignee: Ciba-Geigy Corporation
    Inventor: Hans-Rudolf Waespe
  • Patent number: 4876361
    Abstract: Described is a novel process which can be carried out as a single-stage synthesis for the production of substituted and/or b,d- ortho-fused thiophenes. Serving as starting compounds and .alpha.-methylene ketones which are reacted in an preferably alcoholic solvent with bromine whereafter the formed intermediate product after separation from the solvent is reacted directly with a sulphurising agent. Preferably under reflux conditions in a suitable solvent to form the end product.In this way also hitherto unknown ortho-fused thiophene compounds are synthesized more especially those with 5 or 9 rings condensed with one another.
    Type: Grant
    Filed: December 7, 1987
    Date of Patent: October 24, 1989
    Assignee: Rita von der Haar-Czogalla
    Inventor: Claus-D. Czogalla
  • Patent number: 4874876
    Abstract: The present invention provides a process for the preparation of 2-(2-thienyl)-ethylamine and derivatives thereof having the general formula: ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or taken together form a phenyl ring.
    Type: Grant
    Filed: November 2, 1988
    Date of Patent: October 17, 1989
    Assignee: Occidental Chemical Corporation
    Inventors: Neil J. O'Reilly, Henry C. Lin
  • Patent number: 4874792
    Abstract: This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.
    Type: Grant
    Filed: March 25, 1988
    Date of Patent: October 17, 1989
    Assignee: Smithkline Beckman Corporation
    Inventors: John G. Gleason, Ralph F. Hall, Thomas W. Ku, Carl D. Perchonock
  • Patent number: 4873241
    Abstract: 2-Amino-N-(2-phenylindan-2-yl)acetamides of the following formula are provided ##STR1## wherein, a=0 to 3,R.sub.1, R.sub.2 and R.sub.3 are independently selected from hydrogen and methyl,R.sub.4 is hydrogen or C.sub.1 -C.sub.4 alkyl,R.sub.5 is selected from hydrogen, C.sub.1 -C.sub.4 alkyl, cyclopropyl and (aminomethyl)carbonyl, orR.sub.4 and R.sub.5 taken together with the nitrogen atom to which they are attached from a heterocyclic ring selected from pyrrolidinyl, piperidinyl and morpholinyl, orR.sub.3 and R.sub.4 taken together with the carbon atom and nitrogen atom to which they are respectively attached form a heterocyclic ring selected from pyrrolidinyl and piperidinyl, andR.sub.6 is selected from hydrogen, halogen, C.sub.1 -C.sub.4 alkoxy, trifluoromethyl, C.sub.1 -C.sub.4 alkyl and combinations thereof.The compounds have antiepileptic or antihypoxia activity.
    Type: Grant
    Filed: October 31, 1988
    Date of Patent: October 10, 1989
    Assignee: Fisons Corporation
    Inventors: James J. Napier, Ronald C. Griffith
  • Patent number: 4871855
    Abstract: An osmium-catalyzed method of addition to an olefin. In the method of asymmetric dihydroxylation of the present invention, an olefin, a chiral ligand, an organic solvent, water, and aamine oxide and an osmium-containing compound are combined. In the method of asymmetric oxyamination of the present invention, an olefin, a chiral ligand, an organic solvent, water, an amine derivative and an osmium-containing compound are combined. In the method of asymmetric diamination of the present invention, an olefin, a chiral ligand, an organic solvent, a metallo-chloramine derivative or an amine derivative and an osmium-containing compound are combined. In one embodiment, an olefin, a chiral ligand which is a dihydroquinidine derivative or a dihydroquinine derivative, acetone, water, N-methyl morpholine N-oxide and osmium tetroxide are combined to effect asymmetric dihydroxylation of the olefin.
    Type: Grant
    Filed: February 23, 1988
    Date of Patent: October 3, 1989
    Assignee: Massachusetts Institute of Technology
    Inventors: Istvan E. Marko, K. Barry Sharpless
  • Patent number: 4870098
    Abstract: This invention encompasses compounds of Formula I ##STR1## and the pharmaceutically acceptable salts and geometrical and optical isomers thereof wherein:Alk is alkylene or hydroxyalkylene containing 1-6 carbon atoms;Ar is 5,6,7,8-tetrahydro-1-naphthalenyl or phenyl optionally substituted with one or more substituents selected from lower alkyl containing 1 to 6 carbon atoms, hydroxy, lower alkoxy containing 1 to 6 carbon atoms, or lower alkanoyl containing 1 to 6 carbon atoms;R is hydrogen and lower alkyl containing 1 to 6 carbon atoms;X, Y, and Z are each independently O or S with S optionally oxidized to S.dbd.O;m is an integer from 0 to 3;n is an integer from 0 to 5.The compounds are useful as anti-allergy agents and anti-inflammatory agents.
    Type: Grant
    Filed: January 17, 1989
    Date of Patent: September 26, 1989
    Assignee: G. D. Searle & Co.
    Inventors: Michael A. Stealey, Richard M. Weier
  • Patent number: 4866179
    Abstract: An improved method of catalytic gaseous chemical synthesis of pyridine by reaction of ammonia and a carbonyl compound, preferably with added hydrogen, is described herein. The process employs as the catalyst a crystalline aluminosilicate zeolite which has been ion exchanged with a Group VIII metal of the Periodic Table. The preferred metal is palladium. Suitably, the Group VIII metal is present in an amount of about 0.01% to 5% by weight of the catalyst, preferably 0.1% to 2%. The crystalline aluminosilicate zeolite catalyst suitably has a silica to alumina mole rate of at least 15, preferably 30 to 200, and optimally, about 120 to 150. The process of the invention provides a high and selective yield of pyridine over a prolonged reaction period, and affords facile restorability of the catalyst.
    Type: Grant
    Filed: June 6, 1988
    Date of Patent: September 12, 1989
    Assignee: Dairen Chemical Corporation
    Inventors: Wan J. Cheng, Fu S. Lin, Yuh L. Jong, Fu J. Huang
  • Patent number: 4866077
    Abstract: The present invention relates to novel compounds of the following formula, where the dotted line designates an optional bond: ##STR1## wherein "het" designates a five membered heterocyclic ring which may include 1 or 2 double bonds and 1-4 heteroatoms selected from nitrogen, oxygen or sulphur, provided that "het" may not designate a 1,2,4- or 1,3,4-oxadiazole;R.sup.1 is selected from hydrogen, lower alkyl, optionally substituted with phenyl which may be substituted with halogen, lower alkyl, or lower alkoxy, or a group R.sup.6 --CO--NH--CH.sub.2 -- or R.sup.6 --O--CO--, wherein R.sup.6 is lower alkyl, branched or unbranched, or phenyl optionally substituted with halogen, trifluoromethyl, lower alkyl, hydroxy, lower alkoxy, or lower acyloxy;R.sup.2 and R.sup.
    Type: Grant
    Filed: June 22, 1988
    Date of Patent: September 12, 1989
    Assignee: H. Lundbeck A/S
    Inventors: Klaus P. Bogeso, Klaus G. Jensen, Ejner K. Moltzen, Henrik Pedersen
  • Patent number: 4851432
    Abstract: This invention relates to the therapeutic uses of oligomers of 15-dehydroprostaglandin B.sub.1 and oligomers of 16, 16'-dimethyl-15-dehydro PGB.sub.1 and oligomers or other 16 carbon substituted 15-dehydro PGB.sub.1 compounds (hereinafter referred to as oligomers of PGB.sub.1) in tissue ischemia, hyposix and anoxia, (hereinafter referred to collectively as tissue ischemia) and in protecting isolated organs (hearts, kidneys etc.) and cells (whole blood, erythrocytes, platelets, etc.) during in vitro transfer and storage; and as a phamacological agent in abnormal conditions in humans and animals in which alteration in cellular calcium is a mediator in the disease process.
    Type: Grant
    Filed: May 21, 1987
    Date of Patent: July 25, 1989
    Inventor: Thomas M. Devlin
  • Patent number: 4849414
    Abstract: Compounds of the formula ##STR1## wherein X is various amino or imino acids and esters are disclosed. These compounds are useful as anti-hypertensive agents due to their angiotensin converting enzyme inhibition activity and depending upon the definition of X may also be useful as analgesics due to their enkephalinase inhibition activity.
    Type: Grant
    Filed: May 20, 1987
    Date of Patent: July 18, 1989
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Melanie J. Loots, Donald S. Karanewsky
  • Patent number: 4849525
    Abstract: Compounds of the formula ##STR1## and their pharmaceutically acceptable salts wherein Z completes a cycloalkyl ring, a substituted cycloalkyl ring, a cycloalkenyl ring, a substituted cycloalkenyl ring or a saturated heteroalkyl ring; R.sub.2 is lower alkyl, aralkyl or aminoalkyl and X is an amino or imino acid. The compounds possess angiotensin converting enzyme inhibition activity.
    Type: Grant
    Filed: September 21, 1987
    Date of Patent: July 18, 1989
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Harold N. Weller, III, Eric M. Gordon
  • Patent number: 4847288
    Abstract: The present invention relates to compounds which are allenyl amines, more specifically, .beta.-ethenylidene-(substituted)ethanamines, possessing antihypertensive activity. They are prepared by a noval reaction of a protected N,N-bis(trimethylsilyl)-4-methoxy-2-butynylamine compound with a metallo-organic compound, with subsequent removal of the silyl protecting groups to provide the desired compound.
    Type: Grant
    Filed: February 8, 1988
    Date of Patent: July 11, 1989
    Assignee: Merrell Dow Pharmaceuticals Inc.
    Inventors: James R. McCarthy, Thomas M. Bargar, Charlotte L. Barney, Donald P. Matthews, Robert J. Broersma